University of Pittsburgh Cancer Institute, Hospital, Pittsburgh, PA, USA.
Cancer Biol Ther. 2010 Mar 15;9(6):417-22. doi: 10.4161/cbt.9.6.11392. Epub 2010 Mar 3.
Apoptosis is a critical process for the maintenance of tissue homeostasis and prevention of tumorigenesis. The members of the Bcl-2 family of proteins are the central regulators of the intrinsic apoptotic pathway. Within the Bcl-2 family, the BH3-only subfamily of proteins is tasked with sensing a broad range of apoptotic stimuli and transmitting this signal to other Bcl-2 proteins to initiate programmed cell death. This family of proteins is highly regulated at both transcriptional and post-translational levels, as well as by prominent protein-protein interactions among the family members. Bcl-2 family proteins are often deregulated in cancer, with overexpression of antiapoptotic members, as well as mutations or defects in proapoptotic members. These proteins have been the subject of intensive study for many years and the complex relationships between their regulation and tumorigenesis have spawned a new thinking about cancer treatment. New generations of small molecule Bcl-2 family inhibitors and BH3 and SMAC mimetics have brought new optimism to the pursuit of more individualized and effective cancer therapies.
细胞凋亡对于维持组织内环境稳定和预防肿瘤发生至关重要。Bcl-2 家族蛋白是内在细胞凋亡途径的核心调控因子。在 Bcl-2 家族中,BH3 仅亚家族蛋白负责感知广泛的凋亡刺激,并将此信号传递给其他 Bcl-2 蛋白,从而启动程序性细胞死亡。该蛋白家族在转录和翻译后水平以及家族成员之间的显著蛋白-蛋白相互作用方面受到高度调控。Bcl-2 家族蛋白在癌症中经常失调,抗凋亡成员过度表达,以及促凋亡成员发生突变或缺陷。这些蛋白多年来一直是深入研究的对象,它们的调控与肿瘤发生之间的复杂关系催生了一种新的癌症治疗思路。新一代小分子 Bcl-2 家族抑制剂和 BH3 和 SMAC 模拟物为追求更个体化和有效的癌症治疗带来了新的希望。